LSIPR spoke to Jörg Thomaier, chief IP counsel at Bayer, about the state of protection in emerging jurisdictions and the challenges the global company faces in asserting its IP across the world.
In March 2012, global pharmaceutical company Bayer was dealt a blow which would mark a significant turning point for the entire industry.
In India, the Controller of Patents issued the country’s first ever compulsory licence, forcing Bayer to license its patented cancer drug Nexavar (sorafenib) to Natco, a local generics company, which could then sell the drug at a cheaper price.
The controller said that Bayer, which celebrated its 150th anniversary in August, had not made Nexavar publicly available at a reasonably affordable price or sufficiently “worked the patent in India”.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Bayer, Jörg Thomaier, IP strategy, Nexavar, India